In the 18-month trial, people in the early stages of Alzheimer’s who received infusions of donanemab showed 35 per cent less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.
The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer’s.
A similar amyloid-targeting drug, Eisai and Biogen’s Leqembi, recently hit the market with similar evidence that it could modestly slow Alzheimer’s — and also some safety concerns, brain swelling or small brain bleeds.
Read Related Also: Mila Kunis and Ashton Kutcher ‘always had a little spark’
Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.
The preliminary study results haven’t been vetted by outside experts.
Indianapolis-based Lilly plans to release more details at an international Alzheimer’s meeting this summer and is seeking Food and Drug Administration approval of the drug.
Sign up here to receive our daily newsletters and breaking news alerts, sent straight to your inbox.
